📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
226 announcements match the current filters (relevance ≥ 5).
Apollo Hospitals Sets June 24 Shareholder Meeting for Major Restructuring and Merger Scheme
Apollo Hospitals (AHEL) has scheduled an NCLT-convened meeting for equity shareholders on June 24, 2026, to vote on a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, the merger of Keimed Private Limited, and the involvement of Apollo Healthtech. This consolidation aims to streamline the company's pharmacy distribution and digital health platforms. Shareholders as of the cut-off date of June 17, 2026, are eligible to participate in the voting process via remote e-voting starting June 20, 2026.
Key Highlights
NCLT-convened meeting of equity shareholders scheduled for June 24, 2026, via Video Conferencing.
Cut-off date for determining voting eligibility is June 17, 2026.
Remote e-voting period is set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).
The scheme involves a composite arrangement between AHEL, Apollo Healthco, Keimed Private Ltd, and Apollo Healthtech.
Valuation reports and fairness opinions were finalized in June 2025 by KPMG, BDO, and Axis Capital.
👀 What to Watch
Investors should review the specific share entitlement ratios provided in the valuation reports to understand the dilutive or accretive impact of the Keimed merger. This is a critical structural change for Apollo's digital and pharmacy ecosystem and requires a vote by June 24.
Apollo Hospitals Schedules June 24 Shareholder Meeting for Major Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (AHEL) has announced an NCLT-convened meeting of equity shareholders on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to consolidate the group's pharmacy distribution and digital health business (Apollo 24/7). Shareholders as of the June 17, 2026, cut-off date are eligible to vote on this proposal, which is a critical step toward final legal approval for the restructuring. This move is expected to streamline operations and potentially unlock value in the high-growth digital health segment.
Key Highlights
NCLT-convened meeting of equity shareholders scheduled for June 24, 2026, via Video Conferencing.
Scheme involves the merger of Keimed Private Limited and Apollo Healthco into Apollo Healthtech Limited.
Remote e-voting period is set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).
Joint valuation report provided by KPMG and BDO with a fairness opinion from Axis Capital Limited.
The cut-off date for determining shareholder voting eligibility is June 17, 2026.
👀 What to Watch
Investors should review the scheme details and participate in the voting process as this restructuring significantly impacts the company's digital and pharmacy asset valuation.
Apollo Hospitals Schedules Shareholder Meeting on June 24 for Composite Scheme of Arrangement
Apollo Hospitals (AHEL) has announced an NCLT-convened meeting of equity shareholders on June 24, 2026, to approve a major composite scheme of arrangement. The scheme involves the demerger of an identified business undertaking and the merger of Apollo Healthco and Keimed Private Limited into Apollo Healthtech Limited. This restructuring is a strategic move to consolidate the pharmacy distribution and digital health business (Apollo 24/7) under a streamlined structure. Shareholders as of the June 17, 2026, cut-off date are eligible to vote on the proposal.
Key Highlights
NCLT-convened meeting scheduled for June 24, 2026, at 2:30 PM via Video Conferencing.
Scheme involves Apollo Hospitals, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.
Remote e-voting period starts on June 20, 2026, and ends on June 23, 2026.
The arrangement follows regulatory approvals including the CCI order and observation letters from BSE and NSE issued in December 2025.
The restructuring aims to integrate the pharmacy supply chain and digital health platform to unlock value.
👀 What to Watch
Investors should review the share entitlement ratios provided in the valuation reports to understand the impact on their holdings. The consolidation of Keimed is expected to be margin-accretive for the pharmacy business, making this a key development to support.
Apollo Hospitals Sets June 24, 2026 Meeting for Major Composite Scheme of Arrangement
Apollo Hospitals (AHEL) has scheduled a court-convened shareholder meeting on June 24, 2026, to seek approval for a significant composite scheme of arrangement. The restructuring involves Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited, aiming to consolidate the pharmacy distribution and digital health ecosystem. Shareholders as of the June 17, 2026, cut-off date are eligible to vote on the proposal, which has already received necessary observations from BSE and NSE and approval from the CCI. This move is a critical step in the company's long-term strategy to streamline its health-tech and supply chain operations.
Key Highlights
Court-convened meeting scheduled for June 24, 2026, via Video Conferencing per NCLT Chennai orders.
Scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech Limited.
Voting eligibility is determined by a cut-off date of June 17, 2026, with remote e-voting from June 20-23.
The arrangement includes a joint valuation report from KPMG and BDO and a fairness opinion from Axis Capital.
The restructuring follows regulatory clearances including a CCI order and stock exchange observation letters from December 2025.
👀 What to Watch
Investors should support the restructuring as it consolidates the pharmacy supply chain and digital assets, which is expected to improve operational efficiency. Review the specific share entitlement ratios in the valuation reports to understand the impact on individual holdings.
Apollo Hospitals Merges Cradle & Fertility Units with Cloudnine in INR 1,550 Cr Deal
Apollo Health and Lifestyle Limited (AHLL), a subsidiary of Apollo Hospitals, is merging its 'Apollo Cradle' and 'Apollo Fertility' businesses with 'Cloudnine' to create a dominant maternity and fertility platform. The transaction values AHLL's specific verticals at INR 1,550 Crores, which will be realized through a combination of cash and a 9.9% equity stake in the merged entity. This strategic move makes AHLL the largest non-financial shareholder in the combined platform, which will operate over 55 centers across India. The deal is backed by marquee investors including Temasek and TPG, aiming to synergize operations and expand into Tier 1 and 2 markets.
Key Highlights
AHLL's Mother & Child and Fertility verticals valued at INR 1,550 Crores in the combination deal.
Apollo Health and Lifestyle to hold a 9.9% equity stake and a board seat in the combined entity.
The combined platform will operate 55+ centers, creating one of India's largest integrated maternity networks.
Transaction involves a cash component and is subject to regulatory approvals including the CCI.
👀 What to Watch
Investors should view this as a significant value-unlocking event for Apollo's retail healthcare segment. Monitor the completion of regulatory approvals and the potential for improved margins through this consolidated platform.
Apollo Hospitals FY26 PAT up 15% to ₹1,493 Cr; Divests Units for ₹1,550 Cr
Apollo Hospitals reported a strong performance for FY26, with standalone revenue growing 13.7% to ₹9,326.2 crore and PAT increasing 15% to ₹1,492.6 crore. The company announced a major divestment of its specialty and fertility units to Kids Clinic India (Cloudnine) for an enterprise value of ₹1,550 crore, receiving ₹765 crore in cash and a 9.9% equity stake. A final dividend of ₹10 per share (200%) was recommended, and the board approved the merger of Apollo Hospitals North Ltd into the parent company.
Key Highlights
Standalone Revenue for FY26 rose to ₹9,326.2 crore compared to ₹8,202.1 crore in FY25
Net Profit (PAT) grew 15% YoY to ₹1,492.6 crore with an EPS of ₹103.81
Divesting ASHPL and AFCPL to Cloudnine for ₹1,550 crore, retaining a 9.9% equity stake in the buyer
Recommended a final dividend of ₹10 per equity share (200%) with a record date of August 14, 2026
Re-appointed Dr. Prathap C Reddy as Executive Chairman for a further period of two years
👀 What to Watch
The strong earnings growth and strategic divestment to unlock value in the mother-and-child segment are positive catalysts. Investors should monitor the completion of the Cloudnine transaction and the subsequent impact on consolidated margins.
Apollo Pipes COO Parag Dadeech Resigns Effective May 20, 2026
Apollo Pipes Limited has announced the resignation of Mr. Parag Dadeech from the position of Chief Operating Officer (COO) and Senior Management Personnel. The resignation was tendered via email on May 20, 2026, and is effective from the close of business hours on the same day. Mr. Dadeech cited personal health reasons for his inability to continue in the role. This leadership change represents a sudden transition in the company's operational management team.
Key Highlights
Mr. Parag Dadeech resigned as Chief Operating Officer effective from the close of business on May 20, 2026.
The resignation was attributed to personal health reasons as per the formal communication dated May 20, 2026.
The company has filed the necessary disclosures under Regulation 30 of SEBI Listing Regulations.
The transition is immediate, with the resignation being accepted on the same day it was formally submitted.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding a successor to the COO role to ensure operational continuity. While the departure is for personal reasons, the speed of finding a replacement will be critical for maintaining execution momentum.
Apollo Hospitals Q4 FY26 Consolidated Revenue Up 18% YoY; PAT Rises 7%
Apollo Hospitals Enterprise Limited reported an 18% YoY growth in consolidated revenue for Q4 FY26, reaching ’66,055 million. Consolidated EBITDA grew by 36% YoY to ’10,109 million, with margins improving to 15.3%. Profit After Tax (PAT) for the quarter increased by 7% YoY to ’4,120 million, impacted by tax adjustments from the previous year. Additionally, the company announced a strategic combination of its Mother & Child and Fertility businesses with Cloudnine, valuing AHLL's segment at ’1,550 crores.
Key Highlights
Consolidated revenue for Q4 FY26 grew 18% YoY to ’66,055 million.
Consolidated EBITDA increased by 36% YoY to ’10,109 million with a margin of 15.3%.
Healthcare Services revenue rose 16% YoY to ’32,678 million with an occupancy rate of 68%.
Apollo HealthCo total revenue grew 20% YoY to ’25,184 million, while digital cash loss reduced to ’16 crores.
AHLL Mother & Child and Fertility businesses to combine with Cloudnine, valued at ’1,550 crores for cash and a 9.9% equity stake.
👀 What to Watch
Investors should view these results positively due to strong EBITDA growth and the value-unlocking merger of the maternity business with Cloudnine. Monitor the reduction in digital health losses and operational performance of newly commissioned hospital beds.
Apollo Hospitals FY26 PAT Rises 15% to ₹1,493 Cr; Divests Specialty Assets for ₹1,550 Cr
Apollo Hospitals reported a strong financial performance for FY26, with standalone revenue growing 13.7% to ₹9,326 crore and PAT increasing 15% to ₹1,493 crore. The board recommended a final dividend of ₹10 per share and approved a major divestment of its specialty and fertility assets to Kids Clinic India (Cloudnine) for an enterprise value of ₹1,550 crore. This transaction provides ₹765 crore in cash and a strategic 9.9% equity stake in Cloudnine. Additionally, the company is merging its North India subsidiary into the parent entity to streamline its corporate structure.
Key Highlights
Standalone Revenue for FY26 grew to ₹93,262 million compared to ₹82,021 million in the previous year.
Profit After Tax (PAT) increased 15% YoY to ₹14,926 million from ₹12,963 million.
Divesting ASHPL and AFCPL to Cloudnine for ₹15,500 million, receiving ₹7,650 million in cash and 9.9% equity.
Recommended a final dividend of ₹10 per share (200%) with a record date of August 14, 2026.
EBITDA for the full year stood at ₹23,280 million, representing a growth of 13.9% YoY.
👀 What to Watch
Investors should look favorably on the asset divestment as it unlocks value and provides a strategic stake in a specialized player like Cloudnine. The steady double-digit growth in earnings and consistent dividend payout support a long-term hold strategy.
Apollo Hospitals FY26 PAT Rises 15% to ₹1,493 Cr; Announces ₹1,550 Cr Divestment & ₹10 Dividend
Apollo Hospitals reported a strong financial performance for FY26 with standalone PAT growing 15% YoY to ₹14,926 million. The company announced a major strategic divestment of its specialty and fertility units to Kids Clinic India (Cloudnine) for an enterprise value of ₹15,500 million, receiving both cash and a 9.9% equity stake in Cloudnine. Additionally, the board approved the merger of Apollo Hospitals North Ltd into the parent company and recommended a final dividend of ₹10 per share.
Key Highlights
Standalone Revenue for FY26 increased 13.7% YoY to ₹93,262 million compared to ₹82,021 million in FY25.
Divesting ASHPL and AFCPL to Cloudnine for ₹15,500 million, comprising ₹7,650 million cash and 9.9% equity stake.
Standalone EBITDA grew to ₹23,280 million in FY26 from ₹20,442 million in the previous fiscal year.
Recommended a final dividend of ₹10 per equity share (200%) with a record date of August 14, 2026.
Approved the merger of wholly-owned subsidiary Apollo Hospitals North Limited into the company via NCLT route.
👀 What to Watch
The divestment unlocks significant value and provides strategic equity exposure to the maternal care segment; investors should maintain a positive outlook given the steady earnings growth and healthy dividend payout.
Apollo Hospitals FY26 PAT Rises 15% to ₹1,493 Cr; Divests Specialty Units for ₹1,550 Cr
Apollo Hospitals reported a strong performance for FY26, with standalone revenue growing 13.7% YoY to ₹9,326 crore and PAT increasing 15% to ₹1,493 crore. The company announced a significant strategic divestment of its specialty and fertility units to Kids Clinic India (Cloudnine) for an enterprise value of ₹1,550 crore, involving a mix of cash and a 9.9% equity stake in Cloudnine. A final dividend of ₹10 per share was recommended, and the board approved the merger of its North India subsidiary into the parent entity. Leadership continuity is secured with the re-appointment of Dr. Prathap C Reddy as Executive Chairman for two years.
Key Highlights
Standalone Revenue for FY26 increased to ₹9,326.2 crore compared to ₹8,202.1 crore in FY25.
Net Profit (PAT) grew by 15% YoY to ₹1,492.6 crore with an EBITDA of ₹2,328 crore.
Divesting ASHPL and AFCPL units for ₹1,550 crore, receiving ₹765 crore in cash and 9.9% equity in Cloudnine.
Recommended a final dividend of ₹10 per equity share (200%) for the financial year 2025-26.
Approved the merger of wholly-owned subsidiary Apollo Hospitals North Limited into the company.
👀 What to Watch
The divestment of non-core specialty units for a significant cash inflow and equity stake in a leading mother-and-child care brand is a value-unlocking move. Investors should remain positive on the stock given the steady double-digit growth in core hospital operations and healthy dividend payout.
Apollo Hospitals FY26 PAT Rises to ₹14,926M; Divests Stake to Cloudnine for ₹15,500M
Apollo Hospitals reported a strong financial performance for FY26 with a net profit of ₹14,926 million, up from ₹12,963 million in the previous year. The company announced a significant divestment of its specialty and fertility units to Kids Clinic India (Cloudnine) for an enterprise value of ₹15,500 million, which includes ₹7,650 million in cash. Additionally, the board recommended a final dividend of ₹10 per share and approved the merger of its subsidiary, Apollo Hospitals North Limited, into the parent company. These moves indicate a strategic focus on streamlining operations and unlocking capital from non-core assets.
Key Highlights
FY26 Revenue from operations grew to ₹93,262 million compared to ₹82,021 million in FY25.
Net Profit (PAT) for the full year increased by 15% to reach ₹14,926 million.
Divesting stake in ASHPL and AFCPL for ₹15,500M EV, receiving ₹7,650M cash and a 9.9% stake in Cloudnine.
Recommended a final dividend of ₹10 per equity share (200%) with the record date set for August 14, 2026.
Approved the merger of wholly-owned subsidiary Apollo Hospitals North Limited into the parent entity.
👀 What to Watch
Investors should find the divestment and cash inflow positive for the company's balance sheet and future expansion plans. The steady growth in earnings and the ₹10 dividend support a long-term hold strategy.
Apollo Hospitals FY26 PAT up 15% to ₹1,493 Cr; ₹10 Dividend Declared; Divests Assets for ₹1,550 Cr
Apollo Hospitals reported a strong financial performance for FY26, with consolidated revenue growing 13.7% to ₹9,326.2 crore and Profit After Tax (PAT) rising 15% to ₹1,492.6 crore. The Board recommended a final dividend of ₹10 per share (200% of face value) and fixed August 14, 2026, as the record date. Strategically, the company announced the divestment of its fertility and specialty hospital stakes to Cloudnine for an enterprise value of ₹1,550 crore, which includes a ₹765 crore cash component and a 9.9% equity stake in Cloudnine. Additionally, the merger of Apollo Hospitals North Ltd into the parent company was approved to streamline operations.
Key Highlights
Recommended a final dividend of ₹10 per equity share (200% of ₹5 face value) for FY2025-26.
Annual Revenue from operations increased to ₹9,326.2 crore in FY26 compared to ₹8,202.1 crore in FY25.
Net Profit (PAT) for the full year grew by 15% to ₹1,492.6 crore from ₹1,296.3 crore YoY.
Divesting AHLL's stake in specialty and fertility centers to Cloudnine for ₹765 crore cash and a 9.9% equity stake.
Re-appointed Dr. Prathap C Reddy as Executive Chairman for two years and Ms. Rama Bijapurkar as Independent Director for five years.
👀 What to Watch
Investors should take note of the steady double-digit growth in earnings and the strategic unlocking of value through the AHLL divestment. The dividend and the new equity stake in Cloudnine provide both immediate returns and long-term strategic exposure to specialized healthcare segments.
Apollo Hospitals FY26 PAT Rises 15% to ₹1,493 Cr; Announces ₹1,550 Cr Divestment Deal
Apollo Hospitals reported a strong performance for FY26 with standalone net profit rising 15% YoY to ₹14,926 million. The company announced a major strategic divestment of its specialty and fertility hospital stakes to Kids Clinic India (Cloudnine) for an enterprise value of ₹15,500 million, which includes a ₹7,650 million cash component and a 9.9% equity stake in Cloudnine. Shareholders are set to receive a final dividend of ₹10 per share, while the board also approved the merger of its North India subsidiary into the parent company to streamline operations.
Key Highlights
Standalone Revenue for FY26 grew 13.7% YoY to ₹93,262 million compared to ₹82,021 million in FY25
Standalone Net Profit increased to ₹14,926 million with a Basic EPS of ₹103.81
Divestment of ASHPL and AFCPL to Cloudnine for ₹15,500 million enterprise value, securing a 9.9% stake in Cloudnine
Recommended a final dividend of ₹10 per equity share (200% of face value) for FY25-26
Dr. Prathap C Reddy re-appointed as Executive Chairman for a further period of two years from June 2026
👀 What to Watch
The strong earnings growth combined with strategic value unlocking through the Cloudnine deal makes the stock attractive; investors should monitor the completion of the divestment and the integration of the North India subsidiary.
Apollo Hospitals Assigned ICRA AAA (Stable) Credit Rating for Rs 3,000 Crore Bank Facilities
Apollo Hospitals Enterprise Limited has received new credit ratings from ICRA Limited for its bank facilities totaling Rs 3,000 crore. The rating agency assigned an '[ICRA]AAA (Stable)' rating for long-term fund-based term loans amounting to Rs 2,052 crore. Additionally, unallocated long-term/short-term limits of Rs 948 crore were assigned '[ICRA]AAA (Stable) / [ICRA]A1+' ratings. This highest-tier credit rating reflects the company's exceptionally strong financial profile and robust debt-servicing capability.
Key Highlights
ICRA assigned '[ICRA]AAA (Stable)' rating to Rs 2,052 crore long-term fund-based term loans.
Unallocated limits of Rs 948 crore assigned '[ICRA]AAA (Stable) / [ICRA]A1+' ratings.
Total bank facilities rated by ICRA stand at Rs 3,000 crore.
Major lenders include Bank of India (Rs 769 crore), Axis Bank (Rs 500 crore), and State Bank of India (Rs 318 crore).
👀 What to Watch
Investors should view this as a highly positive confirmation of Apollo Hospitals' financial health and low credit risk. The AAA rating ensures the company can continue to borrow at competitive interest rates to fund future growth.
Apollo Micro Systems Transitions to OEM; IDL Explosives Debt-Free with 5x Cash Growth
Apollo Micro Systems (AMS) is undergoing a strategic shift from a Tier-1 electronics supplier to a full-scale Original Equipment Manufacturer (OEM) for defense platforms. The company successfully integrated IDL Explosives, which is now debt-free and has seen its cash position grow 5x year-on-year. AMS has secured critical DPIIT licenses for manufacturing UAVs, missiles, and torpedoes, positioning itself to capture a share of India's targeted ‡3 lakh crore domestic defense production by 2029. The company also reported receiving its first export order, marking its entry into the global defense market.
Key Highlights
Completed 100% acquisition of IDL Explosives; subsidiary now has ‡0 long-term debt and 5x YoY cash growth.
Secured DPIIT licenses for manufacturing UAVs, Missiles, Torpedoes, and indigenous Underwater Mines.
IDL Explosives holds strategic licenses for 50 MTPA HMX and 500 MTPA TNT production.
Received the company's first-ever export order, signaling global expansion beyond the Indian market.
Announced a 10-year vision (FY 2036) to become a global OEM with diversified revenue across Land, Air, and Sea domains.
👀 What to Watch
Investors should view this as a significant value-unlocking phase as the company moves up the value chain from components to platforms. Monitor the execution of the new OEM licenses and the scaling of the IDL Explosives business as key growth drivers.
Apollo Micro Systems Transitions to OEM; Completes 100% IDL Explosives Acquisition
Apollo Micro Systems is transitioning from a Tier-1 electronics supplier to a global Original Equipment Manufacturer (OEM) for defense platforms. The company has completed the 100% acquisition of IDL Explosives, which is now debt-free with a 5x year-on-year increase in cash position. Apollo has secured critical DPIIT licenses for manufacturing UAVs, missiles, and torpedoes, and has successfully received its first export order. Management has outlined 'Vision 2036' to establish a global presence across Land, Air, and Sea domains.
Key Highlights
Completed 100% acquisition of IDL Explosives with licenses for 550 MTPA of HMX and TNT.
IDL Explosives restructured to zero long-term debt with cash growth of approximately 5x YoY.
Secured DPIIT industrial licenses for UAVs, Missiles, Torpedoes, and Loitering Munitions.
Received the company's first-ever export order, signaling entry into the global defense market.
Strategic shift from being a subsystem supplier to a platform-owning OEM with proprietary IP.
👀 What to Watch
Investors should monitor the company's transition into high-margin OEM roles and the scaling of its new UAV and missile manufacturing capabilities. The debt-free status of the newly acquired IDL Explosives and the receipt of the first export order are significant de-risking milestones.
Apollo Micro Systems Reports Record FY26 PAT of ₹107.4 Cr, Up 90.5% YoY; Order Book at ₹1432 Cr
Apollo Micro Systems delivered a breakthrough performance in FY26, with annual revenue surging 61% to ₹904.32 Cr and PAT growing 90.5% to ₹107.38 Cr. The company achieved its highest-ever quarterly revenue of ₹293.26 Cr in Q4FY26, marking an 81.3% YoY growth. Profitability margins improved significantly, with the annual PAT margin rising from 10% to 12%. The growth is backed by a robust consolidated order book of ₹1432 Cr and strategic milestones including UAV manufacturing licenses and the company's first export order.
Key Highlights
FY26 Revenue grew 60.9% YoY to ₹904.32 Cr, with Q4FY26 revenue hitting a record ₹293.26 Cr.
Annual Profit After Tax (PAT) surged 90.5% YoY to ₹107.38 Cr, while Q4 PAT jumped 163.5% YoY.
Consolidated order book stands at a strong ₹1432 Cr as of March 31, 2026.
EBITDA (excluding other income) for FY26 increased by 68.8% YoY to ₹218.16 Cr.
Strategic developments include the acquisition of IDL Explosives and receipt of a DPIIT license for UAV manufacture.
👀 What to Watch
The company's massive growth in profitability and strong order book visibility suggest a robust growth trajectory in the defense electronics space. Investors should monitor the integration of new acquisitions and the execution of the UAV manufacturing license as key future catalysts.
Apollo Tyres Q4 FY26: Revenue Up 14%, Net Debt/EBITDA at 0.4x, ₹35B CapEx Planned for FY27
Apollo Tyres reported a strong Q4 FY26 with consolidated revenue growing 14% YoY to INR 73.4 billion and EBITDA margins expanding to 14.6%. The company significantly strengthened its balance sheet, reducing Net Debt/EBITDA to 0.4x from 3.2x in 2020. Management has outlined a substantial CapEx of INR 35 billion for FY27, primarily focused on capacity expansion in India. However, near-term margins face pressure from rising raw material costs expected to increase in high teens, which the company is mitigating through price hikes of 6-8%.
Key Highlights
Consolidated revenue grew 14% YoY to INR 73.4 billion with an EBITDA margin of 14.6%.
Net Debt to EBITDA ratio improved dramatically to 0.4x, providing significant financial flexibility.
Announced FY27 CapEx of INR 35 billion, with INR 30 billion allocated for India capacity expansion.
India operations saw high teens volume growth in both replacement and OEM segments.
Transitioning to a 25% tax regime in FY27, resulting in a one-time deferred tax gain of INR 5.7 billion.
👀 What to Watch
Investors should monitor the company's ability to pass on the high-teens raw material inflation through further price hikes. The significant deleveraging and planned capacity expansion signal strong long-term growth potential despite near-term cost headwinds.
Apollo Micro Systems Recommends Re 0.25 Dividend and Announces Management Changes
Apollo Micro Systems has approved its audited financial results for the fiscal year ending March 31, 2026, with the statutory auditor issuing an unmodified opinion. The Board recommended a final dividend of Re 0.25 (0.25 paisa) per equity share of face value Rs. 1 for shareholder approval. Significant management updates include the resignation of Ms. Rukhya Parveen as Company Secretary and the appointment of Mr. G. Seshadri Vasan as the new Compliance Officer effective June 1, 2026. The company also re-appointed its cost and internal auditors for the 2026-2027 financial year to ensure continued regulatory compliance.
Key Highlights
Recommended a final dividend of Re 0.25 (0.25 paisa) per equity share of face value Rs. 1 for FY 2025-26
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026
Appointed Mr. G. Seshadri Vasan as Company Secretary and Compliance Officer effective June 1, 2026
Re-appointed M/s E Sateesh Reddy & Associates as Internal Auditors for the financial year 2026-2027
Statutory auditors S.T. Mohite & Co. issued an audit report with an unmodified opinion for the full fiscal year
👀 What to Watch
Investors should monitor the full financial results to evaluate the company's growth trajectory and margin performance. The unmodified audit opinion and dividend recommendation signal stable corporate governance and financial health.
